SLXN (Silexion Therapeutics) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Days Payable?

Silexion Therapeutics's average Accounts Payable for the three months ended in Dec. 2024 was $0.86 Mil. Silexion Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Silexion Therapeutics's Days Payable or its related term are showing as below:

SLXN's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 123.485
* Ranked among companies with meaningful Days Payable only.

Silexion Therapeutics's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Silexion Therapeutics Days Payable Historical Data

The historical data trend for Silexion Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Days Payable Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Days Payable

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Silexion Therapeutics's Days Payable

For the Biotechnology subindustry, Silexion Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Silexion Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Silexion Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (0.319	+	0.929)	/	2 )	/	0	*	365
=	0.624					/	0	*	365
=	N/A

Silexion Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0.799	+	0.929)	/	2 )	/	0	*	365 / 4
=	0.864					/	0	*	365 / 4
=	N/A

Silexion Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871

Website

https://www.silexion.com

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.